Add To...

    NVAX  Novavax Inc.

    Exchange

    NASDAQ

    Sector

    Health Care

    Industry

    Biotechnology: Biological Products (No Diagnostic Substances)

    Market Cap.

    291.8M

    Vuru Grade

    26.82/100

    Current Price

    $1.93
    +0.01 (+0.52%)

    Growth Price

    $-0.90
    Why is this negative?

    Stability Price

    $-27.52
    Why is this negative?

    Company Overview

    Management
    Financial Strength
    Economic Moat
    Dividends & Buybacks

    Company Metrics

    • 0 P/E
    • 13.65 P/S
    • 3.74 P/B
    • -0.225 EPS
    • -107.07% Cash ROIC
    • 2.42 Cash Ratio
    • 0 / 0% Dividend
    • 1.62M Avg. Vol.
    • 113.61M Shares
    • 291.8M Market Cap.

    Company Description

    Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particle platform technology. Its vaccine product candidates target pandemic influenza, including H1N1 and H5N1 strains; seasonal influenza; Respiratory Syncytial Virus; and Varicella Zoster Virus that causes shingles. The company has a joint venture wi...
    more


    Download 10 Years of Financial Statements:
    Income Statement   Balance Sheet   Cash Flow

    News

    News Buzz: Ciena Corporation, Novavax Inc, FuelCell Energy Inc, Velti Plc
    Openglobe - Jun 6, 2013
    Ciena Corporation (NASDAQ:CIEN) stock gained 12.20% to $18.31. The company, on June 6, announced unaudited financial results for its fiscal second quarter ended April 30, 2013.
    Novavax, Inc. (NVAX): Develops Vaccine Candidate To Protect Against Middle ... - iStockAnalyst (press release)
    Novavax Develops Vaccine Candidate for Recently Identified Coronavirus - Wall Street Journal
    NOVAVAX, INC. : NOVAVAX AND ISCONOVA TO COMBINE; NOVAVAX ...
    4-traders (press release) - Jun 4, 2013
    Rockville, MD (June 4, 2013)-/GlobeNewswire, Inc. /-Novavax, Inc. (NASDAQ: NVAX), a leading vaccine development company, seeks to acquire a proprietary adjuvant to provide greater flexibility and control of the development and commercialization of its ...
    Novavax Announces Public Offer for All Outstanding Shares of Isconova - MarketWatch (press release)
    TOP GAINERS Pre Market Today – Novavax Inc, FuelCell Energy, Clovis ...
    Pentagon Post - Jun 6, 2013
    Novavax Incorporated (NASDAQ: NVAX) currently trades at $2.2, up 15.3 percent in Pre-Market with 43,950 share volume. NVAX currently trades -31.06 percent below its 52-week high and 59.17 percent above its 52-week low.
    NOVAVAX, INC. : Flexion Therapeutics Names Frederick Driscoll Chief Financial ...
    4-traders (press release) - May 20, 2013
    WOBURN, Mass., May 20, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer.
    Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer - Wall Street Journal (press release)
    AFTER-HOURS Top Losers – Lululemon Athletica, Omega Protein Corp, Hyster ...
    FxPips.com - Jun 11, 2013
    The following are stocks that declined the most during After Hours trade, as of 5:05 P.M., June 10, 2013. Lululemon Athletica Inc. (NASDAQ: LULU) was trading at $72.96, down -11.3 pct during After Hours on 2,710,000 traded shares. The company was ...
    Biotech News Bundle: Array Biopharma, Vertex, Amgen, Novavax, Celgene ...
    REM - Jun 14, 2013
    Novavax, Inc. (NASDAQ:NVAX) rose 2.09% to $1.95 on volume of 1.61M shares versus average-daily volume of 1.42M shares amid news of continued insider buying.
    Novavax Director Buys 50K Shares and 4 Insider Buys to Note
    Wall St. Cheat Sheet - Jun 15, 2013
    Douglas Richard who is Director at Novavax, Inc. (NASDAQ:NVAX), bought 50,000 shares at $1.90 per share for a total value of $95,000.
    Novavax (NVAX) Insiders See Opportunity, Load Up on Stock
    StreetInsider.com (subscription) - Jun 13, 2013
    Novavax, Inc. (NASDAQ: NVAX) is seeing continued insider buying. This morning, it was disclosed that Director Richard Douglas bought 50,000 shares on 6/12 at $1.90, bringing his stake to 200,000 shares.
    Why To Keep An Eye On These Biotech Stocks?: Cytokinetics, EXACT Sciences ...
    REM - Jun 17, 2013
    Novavax, Inc. (NASDAQ:NVAX) fell -2.56% to $1.90 on volume of 1.22M shares versus average-daily volume of 1.43M shares after its annual shareholder meeting.
    Best 5 & Worst 5 Biotech Stocks : Savient , Rexahn , Hemispherx , Novavax ...
    REM - Jun 6, 2013
    Novavax, Inc. (NASDAQ:NVAX) traded +6.70% higher to close last trading session at $1.91 amid news that its partner, Cadila Pharmaceutical, aimed at launching vaccine for Influenza H1N1 A Virus (swine flu) in India will seek the government's nod in two ...